Mucosal Drug Delivery: Comprehensive Review

Gopal A.Chavhan[1], Nikita E. Bajad[2], Swati P.Deshmukh[3]

[1]Department of Pharmacy, Shraddha Institute of Pharmacy, Washim, Maharashtra, India
[2]Department of Pharmaceutical chemistry, Shraddha Institute of Pharmacy, Washim, Maharashtra, India
[3]Department of Pharmacolgy, Shraddha Institute of Pharmacy, Washim, Maharashtra, India

Abstract

Mucosal drug delivery has emerged as a promising approach for administering therapeutic agents due to the extensive mucosal surface area and its potential for rapid and targeted absorption. It involves the administration of drugs via mucous membranes such as nasal, buccal, pulmonary, vaginal, and gastrointestinal routes. This method can enhance drug bioavailability, minimize systemic side effects, and improve patient compliance compared to traditional delivery systems. Advances in nanotechnology, formulation strategies, and mucoadhesive materials have significantly enhanced the efficacy of mucosal drug delivery by overcoming barriers such as enzymatic degradation and rapid mucociliary clearance. Innovative strategies, including nanoparticle-based systems, hydrogels, and bio adhesive microspheres, have demonstrated potential for controlled and sustained drug release. Additionally, the mucosal immune system offers an opportunity for localized vaccine delivery and immunotherapy. However, challenges remain, such as drug permeability limitations, variability in mucosal properties, and formulation stability. This review discusses the current progress, challenges, and future prospects in the field, highlighting novel technologies that could transform mucosal drug delivery into a mainstream therapeutic modality.

Keywords: Mucosal Routes of Administration, Drug Formulation and Carriers, Mucoadhesion, Permeation Enhancers, Barriers to Mucosal Drug Delivery, Drug Release Mechanisms

INTRODUCTION

Mucosal drug delivery is an innovative approach to administering therapeutic agents directly through the body's mucous membranes, which cover a variety of surfaces such as the respiratory, gastrointestinal, urogenital tracts, and ocular and nasal cavities. This method leverages the vast surface area and rich vascularization of mucosal tissues to facilitate rapid absorption and targeted delivery of drugs. Unlike conventional delivery methods such as oral or intravenous routes, mucosal delivery offers the potential for enhanced bioavailability, reduced systemic side effects, and improved patient compliance due to its non-invasive nature.

The mucosal surfaces present unique opportunities and challenges for drug delivery. The mucus layer provides a protective barrier that can hinder drug absorption, while enzymatic activity in these tissues can lead to the degradation of therapeutic agents before they reach systemic circulation. Despite these barriers, advancements in drug formulation, such as nanoparticles, hydrogels, and mucoadhesive systems, have made it possible to overcome these limitations, providing controlled and sustained release profiles.

Additionally, the mucosal route is increasingly utilized for localized drug action, such as treating respiratory conditions via pulmonary delivery, or for systemic effects, such as delivering hormones through the buccal mucosa. There is also significant interest in exploiting the mucosal immune system for vaccination and

immunotherapy, as mucosal tissues are home to a large number of immune cells that can be targeted for more effective immune responses.

This introduction provides a foundation for understanding the benefits and challenges of mucosal drug delivery and explores the technological advances driving this field towards more efficient and patient-friendly therapeutic options.[1]

MUCOSAL ROUTE OF ADMIRATION

Mucosal drug delivery leverages various mucosal surfaces within the body to deliver therapeutic agents. Each route offers unique advantages and faces distinct challenges based on the anatomy and physiology of the target mucosa. The main mucosal routes of administration include:

1.Oral/Buccal Route:-Description: Involves the administration of drugs through the mucosal lining of the mouth, specifically the buccal (cheek) or sublingual (under the tongue) areas.

Advantages: Provides a rapid onset of action and bypasses the first-pass metabolism in the liver, leading to higher bioavailability for certain drugs

2.Nasal Route:-Description:- Drug delivery through the nasal cavity, which is highly vascularized and provides a direct pathway for systemic absorption.

Advantages: Enables rapid absorption into the bloodstream, making it suitable for drugs that require a quick onset of action. It also allows for potential direct access to the central nervous system via the olfactory region.

3.Pulmonary Route:-Description: Inhalation of drugs through the respiratory tract, targeting the lungs' extensive surface area for absorption.

Advantages: Enables rapid absorption into the bloodstream, making it suitable for drugs that require a quick onset of action. It also allows for potential direct access to the central nervous system via the olfactory region.

4.Gastrointestinal Route:- Description: Refers to the oral administration of drugs for absorption through the gastrointestinal tract's mucosal lining, including the stomach, small intestine, and colon.

Advantages: Convenient and widely accepted by patients, suitable for both local and systemic effects, and allows for various formulation types (e.g., tablets, capsules).

5.Vaginal Route:- Description: Drug administration through the vaginal mucosa, often used for local treatments (e.g., infections, hormone replacement therapy) or systemic effects (e.g., contraceptives).

Advantages: Provides localized drug delivery with minimal systemic side effects and avoids gastrointestinal degradation and first-pass metabolism.

6.Rectal Route:-Description: Administration of drugs via the rectal mucosa for local or systemic absorption.

Advantages: Useful for patients who cannot take oral medications (e.g., due to vomiting or unconsciousness) and provides a partial avoidance of first-pass metabolism.

7.Ocular Route:-Description: Application of drugs directly to the eye's mucosal surfaces, typically used for local treatments (e.g., glaucoma, infections).

Advantages: Provides direct access to the eye for high local drug concentration and minimal systemic exposure.[2]



Fig(1):- mucosal route of admiration

DRUG FORMULATION AND CARRIER

Mucosal drug delivery involves administering drugs across mucous membranes, such as nasal, oral, rectal, and vaginal tissues, allowing for direct absorption into the systemic circulation. This method bypasses the gastrointestinal tract and first-pass metabolism in the liver, potentially enhancing drug bioavailability.[3]

A)Drug Formulation for Mucosal Delivery:

1.Solutions and Suspensions: Liquid formulations are commonly used for nasal sprays, eye drops, or mouthwashes. They are straightforward to administer but may have limitations in sustaining drug release.

2.Gels and Ointments: These are more viscous than solutions, allowing for prolonged retention at the mucosal site, which can enhance absorption. They are used in formulations for the nasal cavity, oral mucosa, and rectal or vaginal applications.

3.Tablets and Films: Mucoadhesive tablets or films can adhere to mucosal surfaces, providing controlled or sustained drug release. They are suitable for buccal, sublingual, and vaginal routes.

4.Powders and Aerosols: Used for nasal or pulmonary routes, these forms deliver drugs as fine particles for rapid absorption. Dry powder formulations are particularly advantageous for heat-sensitive compounds.

5.Suppositories: Designed for rectal or vaginal administration, these solid formulations melt or dissolve at body temperature, releasing the drug locally or systemically.

B)Drug Carriers for Mucosal Delivery:

1.Liposomes: These are lipid-based vesicles that can encapsulate hydrophilic and hydrophobic drugs, protecting them from degradation and improving mucosal absorption.

2.Nanoparticles: Polymer-based nanoparticles can enhance drug stability and facilitate targeted delivery. They can be engineered to improve adherence to mucosal surfaces.

3.Microspheres: Used to extend drug release, these particles can carry the drug within or on their surfaces, providing controlled delivery over time.

4.Cyclodextrins: These cyclic oligosaccharides can form complexes with drugs to increase solubility and stability, enhancing absorption through mucosal tissues.

5.Hydrogels: Cross-linked polymer networks that can hold large amounts of water, providing a sustained-release system for mucosal delivery.[4][5]

MUCOADHESION

Mucosal drug delivery involves administering drugs across mucous membranes, such as nasal, oral, rectal, and vaginal tissues, allowing for direct absorption into the systemic circulation. This method bypasses the gastrointestinal tract and first-pass metabolism in the liver, potentially enhancing drug bioavailability[6].

A)Drug Formulation for Mucosal Delivery:

1.Solutions and Suspensions: Liquid formulations are commonly used for nasal sprays, eye drops, or mouthwashes. They are straightforward to administer but may have limitations in sustaining drug release.

2.Gels and Ointments: These are more viscous than solutions, allowing for prolonged retention at the mucosal site, which can enhance absorption. They are used in formulations for the nasal cavity, oral mucosa, and rectal or vaginal applications

3.Tablets and Films: Mucoadhesive tablets or films can adhere to mucosal surfaces, providing controlled or sustained drug release. They are suitable for buccal, sublingual, and vaginal routes.

4.Powders and Aerosols: Used for nasal or pulmonary routes, these forms deliver drugs as fine particles for rapid absorption. Dry powder formulations are particularly advantageous for heat-sensitive compounds.

5.Suppositories: Designed for rectal or vaginal administration, these solid formulations melt or dissolve at body temperature, releasing the drug locally or systemically.[7]

B)Drug Carriers for Mucosal Delivery:

1.Polymer Properties:

- Molecular Weight: Higher molecular weight polymers generally exhibit stronger mucoadhesion due to their greater chain length and increased number of interaction sites.
- Charge: Positively charged polymers often exhibit better mucoadhesion because the mucosal layer is negatively charged.
- Hydrophobicity: Polymers that can absorb water and swell tend to exhibit stronger mucoadhesion

2.Mucosal Surface Characteristics:

- Mucus Thickness and Turnover: Areas with a thicker mucus layer may offer a more substantial surface for adhesion. However, regions with high mucus turnover might reduce the duration of mucoadhesion.
- pH and Ionic Strength: The pH and ionic composition of the mucosal surface can influence the interactions between the delivery system and mucus.

3.Environmental Conditions:

- Moisture Content: Sufficient moisture is necessary for the swelling and activation of mucoadhesive materials.
- Application Pressure and Contact Time: Increased pressure and prolonged contact time can improve mucoadhesion.[8]

PERMEATION ENHANCER

Permeation enhancers are substances used in mucosal drug delivery to increase the permeability of the mucosal membrane, facilitating the absorption of drugs that otherwise have poor bioavailability. They help improve the drug's ability to pass through mucosal barriers like the nasal, buccal, vaginal, rectal, or ocular tissues.[9]

A)Mechanism of Action of Permeation Enhancers:

1.Disruption of Mucosal Barrier: Some enhancers temporarily disrupt the mucosal barrier by loosening the tight junctions between cells, allowing larger molecules to pass through.

2.Fluidization of Cell Membranes: By altering the lipid bilayer of cell membranes, permeation enhancers can increase membrane fluidity, promoting the passage of drugs across the cell membrane.

3.Enzyme Inhibition: Certain enhancers inhibit mucosal enzymes that would normally degrade the drug, thereby improving the drug's stability and absorption.

4.Mucolytic Action: Some permeation enhancers can reduce the viscosity of the mucus layer, making it easier for drugs to diffuse through.[11]

B)Common Types of Permeation Enhancers:

1)Surfactants

2)Fatty Acids and Their Derivations

3)Cyclohexatrienes

4)Chelating Agents

5)Chitosan and Its Derivatives

6)Enzyme Inhibitors

7)Alcohols and Polyols[12]

C)Factors Influencing the Choice of Permeation Enhancer

1.Type of Drug: The molecular weight, hydrophilicity, or lipophilicity of the drug affects the choice of enhancer.

2.Site of Administration: Different mucosal sites have varying permeability, requiring site-specific enhancers. For example, nasal mucosa is more permeable than buccal mucosa.

3.Safety and Toxicity: The enhancer must not cause permanent damage to the mucosal tissue or trigger significant side effects.

4.Duration of Effect: Ideally, the permeation enhancement should be temporary, allowing the mucosa to return to its normal state after drug absorption.[13]



Fig(2):-permeation enhance

BARRIERS TO MUCOSAL DRUG DELIVERY

Mucosal drug delivery involves administering medications through mucous membranes, such as those lining the nasal, oral, ocular, gastrointestinal, or vaginal routes. Despite its potential benefits (e.g., rapid onset of action, non-invasiveness), there are significant barriers to effective mucosal drug delivery[14]

1.Mucus Layer

- Protective Function: The mucus layer protects mucosal surfaces by trapping and eliminating foreign particles, including drugs.
- Barrier to Penetration: It acts as a physical and chemical barrier, hindering drug absorption due to its gel-like structure.
- Mucociliary Clearance: In certain areas, such as the nasal or respiratory tract, ciliary movement can clear the mucus along with the drug, reducing its contact time.[15]

2.Enzymatic Degradation

- Enzyme Presence: Mucosal surfaces, especially the gastrointestinal tract, have a high concentration of enzymes that can degrade drugs, reducing their bioavailability.
- Protease Activity: For peptide or protein-based drugs, proteolytic enzymes can break them down before they reach their target.[16]

3.Epithelial Barriers

- Tight Junctions: The epithelial cells in mucosal tissues are linked by tight junctions, limiting paracellular transport and making it challenging for drugs to pass between cells.
- Cellular Uptake Limitations: Some drugs have poor permeability across the epithelial cell membranes, further limiting absorption.[17]

4.Physicochemical Properties of the Drug

- Molecular Size and Weight: Larger molecules struggle to penetrate the mucosal layers.
- Lipid Solubility: Hydrophilic drugs have difficulty crossing the lipid-rich cellular membranes.
- Ionization State: Drugs that ionize at the pH of the mucosal surface may have reduced absorption.

5.pH Variations

- Diverse pH Environments: Different mucosal sites (e.g., acidic stomach vs. neutral intestine) have varying pH levels, which can affect drug stability and absorption.
- Impact on Drug Ionization: Changes in pH can alter the ionization state of a drug, influencing its solubility and permeability.[18]

6.Efflux Mechanisms

- Efflux Transporters (e.g., P-glycoprotein): Some mucosal cells express transport proteins that pump drugs back into the lumen, reducing absorption.[19]

7.Immunological Barriers

- Mucosal Immunity: Mucosal tissues have immune cells that may recognize and attack foreign substances, including drugs.
- Inflammatory Responses: The immune system may respond to drug particles as irritants, causing inflammation and reducing drug absorption.[20]



Fig(3):-Barriers to Mucosal Drug Delivery

DRUG RELEASE MECHANISM

The drug release mechanism in mucosal drug delivery refers to the process by which a drug is liberated from its formulation and becomes available for absorption through the mucosal membrane. The goal is to achieve controlled, sustained, or targeted drug release, optimizing therapeutic effects and minimizing side effects. Various mechanisms can govern how a drug is released from its delivery system.[21]

A.Diffusion-Controlled Release:

- In diffusion-controlled systems, the drug molecules move from a region of high concentration (within the delivery system) to a region of lower concentration (across the mucosal barrier).
- Matrix Systems: The drug is dispersed throughout a matrix, and its release occurs as it diffuses through the matrix material. This can be a polymer gel or a solid dosage form like a tablet.
- Reservoir Systems: The drug is enclosed in a core surrounded by a rate-controlling membrane. The release rate is determined by the diffusion through the membrane.

B.Dissolution-Controlled Release:

- In dissolution-controlled systems, the rate of drug release is dependent on the dissolution of the drug or the carrier material in bodily fluids.
- Erosion-Based Systems: If the delivery system is composed of a dissolvable polymer, the drug release occurs as the polymer erodes in the mucosal fluids.
- Dissolvable Films and Tablets: Formulations like buccal films, lozenges, or nasal tablets dissolve in the presence of mucosal fluids, releasing the drug.

C.Ion-Exchange Release Mechanism:

- The drug is released through an ion-exchange process, where ions present in the mucosal fluids replace ions attached to the drug carrier, liberating the drug.
- Controlled Release: Can be used to provide sustained drug release, particularly for ionic drugs.

D.Controlled Gelation Release:

- Some formulations utilize in-situ gelation, where a liquid formulation converts into a gel upon contact with mucosal fluids (due to changes in temperature, pH, or ionic concentration), providing a sustained release of the drug.

E.Osmotically Controlled Release:

- These systems use osmotic pressure as the driving force for drug release. A semi-permeable membrane allows water to enter the system, creating pressure that pushes the drug out through a delivery orifice.
- Advantages: Provides consistent and controlled drug release, unaffected by environmental conditions such as pH or food intake.

F .Swelling-Controlled Release:

- In swelling-controlled systems, the drug delivery matrix swells upon contact with mucosal fluids, increasing in oleum and allowing the drug to be released.[22]
- Mechanism: Polymers like hydrogels absorb moisture, causing the network to expand and create pathways through which the drug can diffuse.



Fig(4):-drug release mechanism

CONCLUSION

Mucosal drug delivery is an innovative and effective method for administering medications through mucosal surfaces, such as the oral, nasal, rectal, or vaginal cavities. In summary, mucosal drug delivery presents a promising approach to enhancing drug absorption, improving patient compliance, and enabling targeted therapies. However, it requires careful consideration of formulation, immune response, and potential challenges to realize its full potential in clinical practice.

In summary, mucosal drug delivery holds great promise for enhancing therapeutic outcomes across various medical disciplines. Ongoing research and development in this area are expected to lead to more effective, safer, and patient-friendly treatment options in the near future.

REFERENCE

1. Patil, J. S., & Kadam, D. V. (2011). “Mucoadhesive polymers: Means of improving the mucoadhesive properties of drug delivery system.” Journal of Pharmacy and Bioallied Sciences, 3(1), 89-100.
2. Mahajan, H. S., & Deshmukh, S. R. (2012). “Development and evaluation of gel-forming in situ ophthalmic drug delivery system for timolol maleate.” Current Eye Research, 37(5), 386-393.
3. Mishra, B., & Patel, B. B. (2009). “Mucosal drug delivery system: A review.” Current Drug Delivery, 6(3), 274-281.
4. Nagarwal, R. C., & Pandit, J. K. (2009). “Mucosal immunization using microparticles as carriers: Clinical potential.” Indian Journal of Pharmaceutical Sciences, 71(6), 641-647.
5. Kumar, M., & Mishra, D. (2012). “Mucosal drug delivery system: Application of mucoadhesive polymers.” Journal of Advanced Pharmaceutical Technology & Research, 3(3), 204-212.
6. Sharma, P., & Garg, S. (2010). “Orodispersible films: A new approach to oral drug delivery.” International Journal of Pharmaceutical Investigation, 1(2), 98-101.
7. Chaurasia, G. (2011). “A review on pharmaceutical preformulation studies in formulation and development of new drug molecules.” International Journal of Pharmaceutical Sciences and Research, 2(6), 1169-1175.
8. Gupta, P., & Kumar, V. (2011). “Mucoadhesive polymers: A review.” International Journal of Pharma Sciences and Research, 2(6), 1430-1437.
9. Vyas, S. P., & Khar, R. K. (2002). Targeted and Controlled Drug Delivery: Novel Carrier Systems. New Delhi: CBS Publishers.
10. Rao, R., & Diwan, P. V. (1998). “Permeability of drugs through human vaginal and buccal mucosa.” Indian Journal of Pharmaceutical Sciences, 60(1), 21-25.
11. Banerjee, T., & Mitra, S. (2012). “Mucoadhesive systems for therapeutic applications.” Asian Journal of Pharmaceutical and Clinical Research, 5(1), 20-28.
12. Rani, S., & Kumar, S. (2014). “Recent advances in nasal drug delivery system: An overview.” International Journal of Pharmaceutical Sciences Review and Research, 27(2), 87-95.
13. Pandey, P., & Jatana, G. (2013). “Recent advancements in buccal drug delivery system.” Journal of Drug Delivery and Therapeutics, 3(1), 16-22.
14. Nagpal, M., & Singh, S. K. (2011). “Nanocarriers: An emerging platform for targeting drug delivery.” Asian Journal of Biomedical and Pharmaceutical Sciences, 1(1), 16-27.
15. Das, S., & Mohanty, A. (2013). “Mucoadhesive microcapsules of metformin HCl: Formulation and evaluation.” International Journal of Pharmaceutical Sciences and Research, 4(2), 669-675.
16. Sahoo, S., & Kumar, V. (2009). “Mucoadhesive drug delivery systems: An overview.” Journal of Advanced Pharmaceutical Technology & Research, 3(3), 204-212.

17. Singh, A., & Ahuja, N. (2002). “Permeation enhancers for transdermal drug delivery.” Drug Development and Industrial Pharmacy, 28(5), 473-488.
18. Mukherjee, B., & Mahapatra, S. (2005). “Mucoadhesive microcapsules of metformin hydrochloride: A new direction for oral drug delivery.” Acta Poloniae Pharmaceuticals, 62(1), 21-30.
19. Thakur, R. R., & Jain, V. (2006). “Mucosal delivery of vaccines.” Indian Journal of Pharmaceutical Education and Research, 40(4), 181-186.
20. Pandey, S., & Sharma, A. (2011). “Recent trends in mucosal drug delivery systems: A review.” International Journal of Drug Development and Research, 3(4), 35-41.
21. Arora, G., & Sharma, N. (2014). “Mucoadhesive buccal films: Innovations in oral drug delivery.” International Journal of Pharmaceutical Sciences Review and Research, 26(1), 51-56.
22. Ghosal, S. K., & Choudhury, P. K. (2008). “Mucoadhesive polymers: A review.” The Eastern Pharmacist, 39(466), 121-125.
23. Choudhary, D., & Mishra, S. K. (2010). “Formulation and evaluation of mucoadhesive microspheres for nasal delivery.” Indian Journal of Pharmaceutical Sciences, 72(5), 605-609.
24. Chatterjee, A., & Gupta, S. (2015). “Mucoadhesive hydrogels as potential carriers in drug delivery.” Asian Journal of Pharmaceutical and Clinical Research, 8(1), 42-47.